- Home
- PLX vs MCRB Comparison
PLX vs MCRB Comparison
Compare PLX & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- MCRB
- Stock Information
- Founded
- PLX 1993
- MCRB 2010
- Country
- PLX United States
- MCRB United States
- Employees
- PLX N/A
- MCRB N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- PLX Health Care
- MCRB Health Care
- Exchange
- PLX Nasdaq
- MCRB Nasdaq
- Market Cap
- PLX 122.6M
- MCRB 103.7M
- IPO Year
- PLX 1998
- MCRB 2015
- Fundamental
- Price
- PLX $1.46
- MCRB $14.07
- Analyst Decision
- PLX Strong Buy
- MCRB Hold
- Analyst Count
- PLX 1
- MCRB 4
- Target Price
- PLX $15.00
- MCRB $73.67
- AVG Volume (30 Days)
- PLX 1.3M
- MCRB 149.9K
- Earning Date
- PLX 08-13-2025
- MCRB 08-12-2025
- Dividend Yield
- PLX N/A
- MCRB N/A
- EPS Growth
- PLX N/A
- MCRB N/A
- EPS
- PLX 0.05
- MCRB 8.98
- Revenue
- PLX $59,764,000.00
- MCRB N/A
- Revenue This Year
- PLX $65.02
- MCRB N/A
- Revenue Next Year
- PLX $57.34
- MCRB N/A
- P/E Ratio
- PLX $30.21
- MCRB $1.70
- Revenue Growth
- PLX 0.18
- MCRB N/A
- 52 Week Low
- PLX $0.82
- MCRB $6.53
- 52 Week High
- PLX $3.10
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- PLX 46.02
- MCRB 70.42
- Support Level
- PLX $1.36
- MCRB $13.19
- Resistance Level
- PLX $1.54
- MCRB $15.98
- Average True Range (ATR)
- PLX 0.08
- MCRB 1.40
- MACD
- PLX 0.02
- MCRB 0.27
- Stochastic Oscillator
- PLX 41.67
- MCRB 72.62
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.